Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY

(MRK)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
08/15/2019 08/16/2019 08/19/2019 08/20/2019 08/21/2019 Date
83.46(c) 85.06(c) 86.19(c) 85.65(c) 86.975 Last
9 106 523 8 736 862 7 304 657 5 893 708 3 584 552 Volume
+0.07% +1.92% +1.33% -0.63% +1.55% Change
More quotes
Financials (USD)
Sales 2019 45 867 M
EBIT 2019 15 606 M
Net income 2019 10 456 M
Debt 2019 19 507 M
Yield 2019 2,56%
Sales 2020 48 470 M
EBIT 2020 16 835 M
Net income 2020 12 216 M
Debt 2020 16 542 M
Yield 2020 2,74%
P/E ratio 2019 21,6x
P/E ratio 2020 17,6x
EV / Sales2019 5,21x
EV / Sales2020 4,87x
Capitalization 219 B
More Financials
Company
Merck and Company specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (73.4%): for treating hypertension, osteoporosis, atherosclerosis, respiratory,... 
Sector
Pharmaceuticals
Calendar
09/13Ex-dividend day for
More about the company
Surperformance© ratings of Merck and Company
Trading Rating : Investor Rating :
More Ratings
Latest news on MERCK AND COMPANY
08/16Correction to AstraZeneca's Lynparza Clinical Trial Article on Wednesday
DJ
08/16JOHNSON & JOHNSON : Ebola Crisis-The Vaccines Debate
AQ
08/15MERCK AND : AstraZeneca and Merck - LYNPARZA Phase 3 PAOLA-1 trial Met Primary E..
AQ
08/14MERCK AND : LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Met Primary Endpoint as F..
BU
08/14ASTRAZENECA : Lynparza Phase III PAOLA-1 trial met primary endpoint
AQ
08/14AstraZeneca's Lynparza Successful in Second Ovarian Cancer Phase 3 Study
DJ
08/12MARKET SNAPSHOT: Dow Closes 390 Points Lower, Loses Grip On 26,000 As 10-year..
DJ
08/12INTEC PHARMA : Reports Second Quarter 2019 Financial Results and Business Update
AQ
08/09Canada enacts drug price crackdown, in blow to pharmaceutical industry
RE
08/09VETERINARY VACCINE MARKET IS EXPECTE : Elanco, Merck, Hester Biosciences, MVP La..
AQ
More news
Analyst Recommendations on MERCK AND COMPANY
More recommendations
Sector news : Pharmaceuticals - NEC
05:45aSlowing Share Buybacks Remove a Pillar of Stock Market
DJ
05:06aAstraZeneca's Imfinzi combination fails advanced lung cancer study
RE
02:47aBayer Sells Pet-Health Unit for $7.6 Billion -- WSJ
DJ
02:27aASTRAZENECA : Imfinzi, Tremelimumab Combination Didn't Meet Primary Endpoint
DJ
08/20Health Care Lower as Litigation, Deal Risks Linger -- Health Care Roundup
DJ
More sector news : Pharmaceuticals - NEC
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Average target price 95,94  $
Last Close Price 85,65  $
Spread / Highest target 22,6%
Spread / Average Target 12,0%
Spread / Lowest Target 2,74%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
James H. Scholefield Chief Information & Digital Officer
Thomas Henry Glocer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY12.09%219 296
JOHNSON & JOHNSON1.20%349 030
ROCHE HOLDING LTD.12.24%239 457
NOVARTIS17.81%205 341
PFIZER-19.40%194 582
AMGEN4.37%123 538